Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 2c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.82), $0.02 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $14.8 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• First BanCorp to Announce 2Q 2026 Results on July 22, 2026
• Playboy to buy back 16.6M shares from Fortress at $1.05 each